Haute MD is the editorial visibility network for distinguished aesthetic, wellness, and specialty physicians, built by Haute Living — a luxury media authority with over 20 years of audience reach across the most financially successful demographics in the United States. Haute MD gives member physicians a premium editorial presence through profiles, professionally written features, treatment coverage, and AI- and search-ready structured content published on HauteLiving.com.

Haute MD is designed for board-certified plastic surgeons, dermatologists, aesthetic physicians, fertility specialists, concierge doctors, and specialty medical professionals in top U.S. markets including New York, Los Angeles, Miami, Chicago, Dallas, Beverly Hills, and Boston.

What does a Haute MD membership include?

Haute MD membership includes a permanent editorial profile on HauteLiving.com, professionally written editorial features and treatment coverage, social amplification across Haute Living's audience, and structured content designed to support discoverability on Google and AI search platforms. Gold and Platinum members also receive dedicated AI Visibility and SEO support. Benefits activate on day one.

How does Haute MD improve AI search visibility?

Haute MD improves AI search visibility by publishing structured physician profiles, editorial features, FAQs, schema markup, and treatment content on HauteLiving.com — a trusted domain indexed by Google News. These assets give AI platforms such as ChatGPT, Google AI Overviews, and Perplexity clear, authoritative context around a physician's specialty, credentials, procedures, and market.

What are the Haute MD membership tiers and pricing?

Haute MD offers three membership tiers: Silver at $500 per year, Gold at $1,500 per year (the most popular tier, which includes AI Visibility and SEO support), and Platinum at $6,000 per year. Founding member pricing locks for life. Applications are reviewed within 48 hours and a full refund is provided if not approved.

Longevity Medicine

What Is Cognitive Testing?

Last reviewed: May 2026 · Haute MD Editorial Team

Cognitive testing uses standardized assessments to quantify memory, attention, processing speed, language, visuospatial function, and executive function. It is increasingly part of longevity workups starting in midlife, both to establish a personal baseline and to detect early changes that may signal mild cognitive impairment (MCI) before clinically obvious symptoms develop.

Types of cognitive testing

Brief screens (5-15 minutes) include the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE) — useful for detecting moderate impairment but insensitive to early or subtle changes. Computerized cognitive batteries (Cambridge Brain Sciences, Cogstate, CNS Vital Signs) take 20-45 minutes and provide more sensitive measurement across multiple cognitive domains with normative comparison and reliable repeat testing. Comprehensive neuropsychological testing (3-5 hours) administered by a neuropsychologist remains the gold standard for diagnosis when significant impairment is suspected — it can distinguish among dementia subtypes, depression-related cognitive symptoms, and normal aging. Baseline testing in midlife — even when results are normal — provides a personal reference point that makes future changes easier to detect.

What cognitive testing detects

Normal aging produces modest decline in processing speed, working memory, and divided attention beginning in the 30s, while crystallized intelligence (vocabulary, accumulated knowledge) is preserved or improves into the 70s. Pathologic changes — early Alzheimer's, vascular cognitive impairment, frontotemporal disease — typically produce disproportionate decline in episodic memory, executive function, or specific domain function out of proportion to age expectation. Subjective cognitive decline (the person notices change before testing confirms it) is increasingly recognized as a meaningful early signal that warrants formal evaluation. Repeat testing over years is more sensitive than any single test — small annual declines tracked against a personal baseline often identify problems years before they would be detected by snapshot screens.

Who should be tested and when

(1) Baseline computerized testing is reasonable in midlife (40s-50s) for anyone interested in tracking cognitive trajectory over time; (2) Anyone with subjective cognitive complaints, particularly affecting daily function or noticed by family; (3) APOE4 carriers and those with strong family history of early dementia may benefit from earlier and more frequent assessment; (4) Patients with cardiovascular risk factors, atrial fibrillation, untreated sleep apnea, or significant alcohol use — all reversible contributors to cognitive decline; (5) Anyone 65+ should have a brief cognitive screen as part of routine care. Results should be interpreted alongside mood (depression frequently mimics cognitive decline), sleep, medication review (anticholinergics, benzodiazepines, opioids impair testing), thyroid function, B12, and other reversible contributors before concluding pathologic decline.

Frequently Asked Questions

How accurate are brief cognitive screens?

MoCA and MMSE have sensitivity of roughly 70-90% for moderate-stage dementia but only 30-50% for MCI. They are useful screens but should not be the only tool when subtle change is the concern.

Can stress or depression affect cognitive testing?

Yes — significantly. Depression frequently produces cognitive complaints and impaired test performance that resolve with treatment ('pseudodementia'). Mood screening should accompany cognitive testing.

How often should I repeat cognitive testing?

Annually for established baselines and high-risk individuals; every 2-3 years for routine midlife monitoring. More frequently if changes are noted or if formal evaluation is in progress.

Do online brain games actually measure cognition?

Commercial 'brain training' apps generally measure performance on their own tasks but do not validate against neuropsychological standards. Use validated computerized batteries (Cambridge Brain Sciences, Cogstate) rather than entertainment apps for clinical baseline tracking.

Get Help Now